Overall, while both BAFF/APRIL-targeted therapies and anti-CD19 monoclonal antibodies aim to modulate B cell function in autoimmune diseases, they do so through different mechanisms that result in varying clinical efficacies and safety profiles. This evidence concerns the gene CD19 and autoimmune disease.